Thomas Watkins - Jun 2, 2022 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
Director
Signature
/s/ H. Thomas Watkins
Stock symbol
VNDA
Transactions as of
Jun 2, 2022
Transactions value $
-$1,529
Form type
4
Date filed
6/3/2022, 04:31 PM
Previous filing
May 2, 2022
Next filing
May 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Options Exercise $62.3K +15K +27.52% $4.15 69.5K Jun 2, 2022 Direct
transaction VNDA Common Stock Sale -$63.8K -6.44K -9.27% $9.90 63.1K Jun 2, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNDA Stock Option (Right to Buy) Options Exercise $0 -15K -100% $0.00* 0 Jun 2, 2022 Common Stock 15K $4.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock sold to satisfy the exercise price of the stock options, which were scheduled to expire June 13, 2022 as reflected in this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $9.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The option vested in 12 equal monthly installments beginning on July 14, 2012.